Worth reading
66In focus
Scored from 1 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
390000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Report on the exercise of stock acquisition rights with exercise price adjustment clauses (Perseus Proteomics Inc. Series 29 Stock Acquisition Rights)
発行・処分する株式数390,000Shares
390,000 shares (new shares)
Terms of the stock acquisition rights
Exercise price
Exercise price: ¥139 (22 June and 24 June). The exercise price is stated as ¥265 from 1 June to 19 June. Details of the adjustment provisions: Not disclosed
Number of Stock Acquisition Rights
Total issued: 36,800; unexercised as of the end of the previous month: 14,299; currently unexercised: 10,399
Most recent equity financing
Stock acquisition rights with exercise price adjustment clauses issued on 5 January 2026 (amount details: Not disclosed)
| Item | Details |
|---|---|
| Type of issuance or disposal | Report on the exercise of stock acquisition rights with exercise price adjustment clauses (Perseus Proteomics Inc. Series 29 Stock Acquisition Rights) |
| Number of shares to be issued or disposed of | 390,000 shares (new shares) |
| Total number of issued shares | 16,999,600 shares (as of the end of the month preceding the month covered) → Not disclosed |
| Exercise price | Exercise price: ¥139 (22 June and 24 June). The exercise price is stated as ¥265 from 1 June to 19 June. Details of the adjustment provisions: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 36,800; unexercised as of the end of the previous month: 14,299; currently unexercised: 10,399 |
| Most recent equity financing | Stock acquisition rights with exercise price adjustment clauses issued on 5 January 2026 (amount details: Not disclosed) |
Items this document does not state (22)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the status of the large-scale exercise.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.